ATAGI update following weekly Covid meeting 7 March

Department of Health

ATAGI update

Latest recommendation updates

ATAGI provided updated advice on COVID-19 booster vaccinations, including recommendation that the Novavax vaccine can be used as a booster in Australians aged 18 and over where an mRNA vaccine is not suitable.

Recent ATAGI considerations

On Wednesday 2 March 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 1 March 2022, over 54 million doses of COVID-19 vaccines have been administered in Australia. ATAGI encourages anyone aged 16 years and over to receive a booster dose as soon as they are eligible.

COVID-19 Vaccine Claims Scheme

ATAGI received an update on the implementation of the COVID-19 vaccine claims scheme.

Evidence relating to second COVID-19 booster doses

ATAGI continues to monitor evidence on the long-term effectiveness of vaccine boosters, including emerging international data on:

  • effectiveness
  • waning of immunity
  • potential need for second booster doses.

Upcoming ATAGI considerations

ATAGI will continue to review current and emerging evidence on COVID-19 booster doses over the coming weeks, including national coverage data, as part of broader considerations around potential need for subsequent doses, particularly coming into the winter months.

COVID-19 vaccine safety

The TGA Weekly Report provides a detailed breakdown of adverse events following immunisation.

Resources and recent statements

ATAGI recommends review of the following key resources:

/Media Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.